THE IN-VITRO ACTIVITY OF FCE-22101 AGAINST GRAM-NEGATIVE AEROBIC ISOLATES RESISTANT TO 3RD-GENERATION CEPHALOSPORINS

The in vitro activity of FCE 22101 against 97 Gram-negative aerobic no socomial isolates was compared with that of ceftriaxone using the agar dilution method. Thirty-four (79%) of the 43 ceftriaxone resistant (M IC > 16 mg/l) isolates were found to be FCE 22101 susceptible (MIC les s-than-or-equal-to 8 mg/l), while of the ceftriaxone susceptible isola tes, only seven Enterobacter cloacae and one Serratia spp strain were FCE 22101 resistant. The new penem may offer an alternative for treati ng nosocomial infections due to aerobic Gram-negative strains resistan t to third generation cephalosporins, provided that clinical studies c onfirm its clinical usefulness.